A quick-access index of popular clinical drug monographs. For complete pharmacology profiles, indications, contraindications, and organ calculators, sign in to access the full workspace.
Converted to abiraterone, which inhibits CYP17, the enzyme required for androgen biosynthesis; androgen- sensitive prostate cancer responds to treatment that decreases androgens Therapeutic outcome: Decreases spread of malignancy
Exact mechanism unknown; relaxes smooth muscle of respiratory system by blocking phosphodiesterase, which increases cyclic AMP; increased cyclic AMP alters intracellular calcium ion movements; produces bronchodilatation, increased pulmonary blood flow, relaxation of respiratory tract Therapeutic outcome: Increased ability to breathe
Increases cell membrane permeability in susceptible fungi by binding to membrane sterols; alters cell membrane, thereby causing leakage of cell components, cell death Therapeutic outcome: Resolution of infection
Inhibits receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)- 1, VEGFR- 2, and VEGFR- 3; inhibits tumor growth and phosphorylation of VEGFR- 2 and VEGF- mediated endothelial cell proliferation Therapeutic outcome: Decreased spread of malignancy
Activated T lymphocytes are the mediators of immunologic rejection, and this product is a selective T- cell costimulation blocker; blocks the CD28 mediated costimulation of T lymphocytes by binding to CD80 and CD86 on antigen- presenting cells; inhibits T lymphocyte proliferation and the production of the cytokines interleukin- 2, interferon- gamma, interleukin- 4, and TNF- alpha. Therapeutic outcome: Absence of kidney transplant rejection
Acts by inhibiting the action of serotonin (5- HT) by binding to serotonin and dopamine receptors; also increases norepinephrine metabolism; has shown little potential for abuse, a good choice in substance abuse Therapeutic outcome: Decreased anxiety
Inhibits abnormal tyrosine kinase associated with growth and development of metastatic medullary thyroid cancer Therapeutic outcome: Decrease in size, spread of tumor
Exact mechanism unknown; appears to decrease polysynaptic responses and block posttetanic potentiation Therapeutic outcome: Absence of seizures; decreased trigeminal neuralgia pain
Inhibits parasite replications, transcription of DNA to RNA by forming complexes with DNA of parasite Therapeutic outcome: Decreased symptoms of malaria, amebiasis
Depresses cerebral cortex, hypothalamus, limbic system, which control activity, aggression; blocks neurotransmission produced by dopamine at synapse; exhibits a strong a-adrenergic, anticholinergic blocking action; mechanism for antipsychotic effects is unclear Therapeutic outcome: Decreased signs and symptoms of psychosis; control of nausea, vomiting, intractable hiccups, decreased anxiety preoperatively
Inhibits transmission of nerve impulses by binding with cholinergic receptor sites, antagonizing action of acetylcholine Therapeutic outcome: Paralysis of body for administration of anesthesia
Competes with physiologic substrate of DNA synthesis, thus interfering with cell replication in the S phase of the cell cycle (before mitosis) Therapeutic outcome: Prevention of rapidly growing malignant cells
Competes with physiologic substrate of DNA synthesis, thus interfering with cell replication in the S phase of the cell cycle (before mitosis) Therapeutic outcome: Prevention of rapidly growing malignant cells
Stimulates erythropoiesis by the same mechanism as endogenous erythropoietin; in response to hypoxia, erythropoietin is produced in the kidney and released into the bloodstream, where it interacts with progenitor stem cells to increase red cell production Therapeutic outcome: Decreased anemia with increased RBCs
Inhibits gastric motility by acting on mucosal receptors responsible for peristalsis Therapeutic outcome: Decreased loose stools
Needed for adequate functioning of female reproductive system; affects release of pituitary gonadatropins, inhibits ovulation, promotes adequate calcium use in bone structure Therapeutic outcome: Decreased tumor size in prostatic cancer; increased estrogen levels in menopause, female hypogonadism
Binds to tumor necrosis factor (TNF), which decreases inflammation and immune response Therapeutic outcome: Decreased pain, inflammation
Depresses cerebral cortex, hypothalamus, limbic system, which control activity and aggression; blocks neurotransmission produced by dopamine at synapse; exhibits strong a-adrenergic and anticholinergic blocking action; mechanism for antipsychotic effects is unclear Therapeutic outcome: Decreased signs and symptoms of psychosis
Inhibits factor Xa; interrupts blood coagulation and inhibits thrombin formation; does not inactivate thrombin (activated factor II) or affect platelets Therapeutic outcome: Prevention of deep vein thrombosis
Prodrug of amprenavir; inhibits human immunodeficiency virus (HIV) protease, which prevents maturation of the infectious virus Therapeutic outcome: Decreasing symptoms of HIV
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and fibroblasts and reversing increased capillary permeability and lysosomal stabilization (systemic); antipruritic, antiinflammatory (topical) Therapeutic outcome: Decreased inflammation
Acts by inhibiting DNA synthesis without interfering with RNA or protein synthesis; incorporates thymidine into DNA, causing direct damage to DNA strands; cell cycle specific (S phase) Therapeutic outcome: Prevention of rapidly growing malignant cells
Not cell cycle specific; topoisomerase II inhibitor, a vesicant; intercalating between DNA base pairs, causing shape change, low free radicals Therapeutic outcome: Prevention of rapidly growing malignant cells